Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43842   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgical neuropathic pain.

    Summary
    EudraCT number
    		 2012-000402-30
    Trial protocol
    		 ES  
    Global end of trial date
    03 Dec 2014

    Results information
    Results version number
    		 v1(current)
    This version publication date
    29 Jul 2016
    First version publication date
    29 Jul 2016
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    ESTEVE-SIGM-205
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Laboratorios Dr. Esteve. S.A. (ESTEVE)
    Sponsor organisation address
    Avda. Mare de Déu de Montserrat, 221, Barcelona, Spain, 08041
    Public contact
    Study Medical Monitor, Laboratorios del Dr. Esteve. S.A, +34 934466000, jcebrecos@esteve.es
    Scientific contact
    Study Medical Monitor, Laboratorios del Dr. Esteve. S.A, +34 934466000, jcebrecos@esteve.es
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Oct 2015
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    03 Dec 2014
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Dec 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the analgesic efficacy of repeated doses of E-52862 in subjects with moderate to severe post-surgical neuropathic pain
    Protection of trial subjects
    The study will be conducted in compliance with the protocol, regulatory requirements, good clinical practice (GCP) and the ethical principles of the latest revision of the Declaration of Helsinki as adopted by the World Medical Association.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    05 Nov 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 116
    Worldwide total number of subjects
    116
    EEA total number of subjects
    116
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    92
    From 65 to 84 years
    24
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 The study was conducted in Spain during 5-Nov-2012 (FSFV) and 3-Dec-2014 (LSLV)

    Pre-assignment
    Screening details
    		 Male and female patients ≥ 18 years with chronic neuropathic pain (DN4 score ≥ 4) of moderate to severe intensity (≥ 4 on the NPRS) caused by a surgery intervention that occurred ≥ 3 months before inclusion in the study

    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Data analyst

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 E-52862
    Arm description
    		 Active arm
    Arm type
    		 Experimental

    Investigational medicinal product name
    E-52862
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    400 mg once a day

    Arm title
    		 Control
    Arm description
    		 Control arm
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    1 capsule of placebo once a day

    Number of subjects in period 1
    		E-52862 Control
    Started
    55
    61
    Completed
    44
    55
    Not completed
    11
    6
         Consent withdrawn by subject
    4
    2
         Physician decision
    -
    1
         Adverse event, non-fatal
    5
    2
         Other
    2
    -
         Not received study medication
    -
    1

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall Trial (overall period)
    Reporting group description
    		 N=115, excluding patient who did not take study medication

    Reporting group values
    		 Overall Trial (overall period) Total
    Number of subjects
    		 116 116
    Age categorical
    Units: Subjects
    Age continuous
    Excluding patient who did not take study medication
    Units: years
        arithmetic mean (standard deviation)
    		 52.55 ( 12.81 ) -
    Gender categorical
    Units: Subjects
        Female
    		 79 79
        Male
    		 37 37

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    E-52862
    Reporting group description
    		 Active arm

    Reporting group title
    Control
    Reporting group description
    		 Control arm

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    Randomised patients who took at least one dose of study medication and with at least one valid baseline and on-treatment efficacy observation

    Primary: NPRS – Average pain – change from baseline to day 28

    		 Close Top of page
    End point title
    		 NPRS – Average pain – change from baseline to day 28
    End point description
    End point type
    Primary
    End point timeframe
    Time specific change from baseline to day 28 in mean pain intensity in the previous 7 days interval measured by a Numerical Pain Rating Scale (NPRS), included in a patient diary (average 24 hour pain)
    End point values
    		 E-52862 Control Full Analysis Set
    Number of subjects analysed
    55
    59
    114
    Units: numeric (pain rating scale)
        arithmetic mean (standard deviation)
    -1.56 ( 1.91 )
    -0.89 ( 1.76 )
    -1.19 ( 1.85 )
    Statistical analysis title
    		 Two-way ANCOVA model
    Statistical analysis description
    Analysis of variance (ANOVA) model including factors for treatment, center (fixed effects) and baseline value (covariate).
    Comparison groups
    E-52862 v Control
    Number of subjects included in analysis
    114
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.029
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (net)
    Point estimate
    -0.87
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.655
         upper limit
    		 -0.091

    Secondary: NPRS – Worst pain – change from baseline to day 28

    		 Close Top of page
    End point title
    		 NPRS – Worst pain – change from baseline to day 28
    End point description
    End point type
    Secondary
    End point timeframe
    Time specific change from baseline to day 28 in mean pain intensity in the previous 7 days interval measured by a Numerical Pain Rating Scale (NPRS), included in a patient diary (worst 24 hour pain)
    End point values
    		 E-52862 Control Full Analysis Set
    Number of subjects analysed
    55
    59
    114
    Units: numeric (pain rating scale)
        arithmetic mean (standard deviation)
    -2 ( 2.266 )
    -1.04 ( 2.092 )
    -1.47 ( 2.215 )
    Statistical analysis title
    		 Two-way ANCOVA model
    Statistical analysis description
    Analysis of variance (ANOVA) model including factors for treatment, center (fixed effects) and baseline value (covariate).
    Comparison groups
    E-52862 v Control
    Number of subjects included in analysis
    114
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.035
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (net)
    Point estimate
    -0.99
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.909
         upper limit
    		 -0.07

    Secondary: 50% responders rate

    		 Close Top of page
    End point title
    		 50% responders rate
    End point description
    End point type
    Secondary
    End point timeframe
    Reduction from baseline to day 28 of at least 50% of the 24-hour average pain score (measured by an NPRS included in the patient diary)
    End point values
    		 E-52862 Control
    Number of subjects analysed
    55
    59
    Units: percent
        number (not applicable)
    16.4
    8.5
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the first IMP intake up to two weeks after the last IMP administration
    Adverse event reporting additional description
    Treatment Emergent Adverse Event are displayed. The AEs that occurred after the first IMP intake are going to be considered as treatment emergent AEs (TEAEs) either serious or not.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    14.0
    Reporting groups
    Reporting group title
    E-52862
    Reporting group description
    		 -

    Reporting group title
    Placebo
    Reporting group description
    		 -

    Serious adverse events
    		 E-52862 Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 55 (5.45%)
    4 / 60 (6.67%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Investigations
    Blood creatine increased, Blood potassium increased, Blood urea increased
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Alanine aminotransferase increased, Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Surgical and medical procedures
    Procedural pain
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal obstruction
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Infection
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 E-52862 Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    50 / 55 (90.91%)
    46 / 60 (76.67%)
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    24 / 55 (43.64%)
    15 / 60 (25.00%)
         occurrences all number
    43
    20
    Headache
         subjects affected / exposed
    17 / 55 (30.91%)
    13 / 60 (21.67%)
         occurrences all number
    46
    29
    Somnolence
         subjects affected / exposed
    3 / 55 (5.45%)
    2 / 60 (3.33%)
         occurrences all number
    4
    2
    General disorders and administration site conditions
    Malaise
         subjects affected / exposed
    3 / 55 (5.45%)
    3 / 60 (5.00%)
         occurrences all number
    5
    3
    Fatigue
         subjects affected / exposed
    2 / 55 (3.64%)
    4 / 60 (6.67%)
         occurrences all number
    5
    6
    Asthenia
         subjects affected / exposed
    2 / 55 (3.64%)
    3 / 60 (5.00%)
         occurrences all number
    2
    3
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    18 / 55 (32.73%)
    4 / 60 (6.67%)
         occurrences all number
    34
    6
    Abdominal pain upper
         subjects affected / exposed
    14 / 55 (25.45%)
    7 / 60 (11.67%)
         occurrences all number
    33
    12
    Vomiting
         subjects affected / exposed
    7 / 55 (12.73%)
    1 / 60 (1.67%)
         occurrences all number
    9
    1
    Dyspepsia
         subjects affected / exposed
    6 / 55 (10.91%)
    1 / 60 (1.67%)
         occurrences all number
    7
    1
    Abdominal discomfort
         subjects affected / exposed
    6 / 55 (10.91%)
    0 / 60 (0.00%)
         occurrences all number
    6
    0
    Dry mouth
         subjects affected / exposed
    5 / 55 (9.09%)
    1 / 60 (1.67%)
         occurrences all number
    6
    2
    Constipation
         subjects affected / exposed
    4 / 55 (7.27%)
    0 / 60 (0.00%)
         occurrences all number
    4
    0
    Flatulence
         subjects affected / exposed
    3 / 55 (5.45%)
    0 / 60 (0.00%)
         occurrences all number
    5
    0
    Diarrhoea
         subjects affected / exposed
    3 / 55 (5.45%)
    1 / 60 (1.67%)
         occurrences all number
    3
    1
    Toothache
         subjects affected / exposed
    1 / 55 (1.82%)
    3 / 60 (5.00%)
         occurrences all number
    1
    6
    Abdominal pain
         subjects affected / exposed
    1 / 55 (1.82%)
    3 / 60 (5.00%)
         occurrences all number
    1
    3
    Skin and subcutaneous tissue disorders
    Hyperhidrosis
         subjects affected / exposed
    4 / 55 (7.27%)
    0 / 60 (0.00%)
         occurrences all number
    5
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    6 / 55 (10.91%)
    2 / 60 (3.33%)
         occurrences all number
    10
    2
    Insomnia
         subjects affected / exposed
    6 / 55 (10.91%)
    4 / 60 (6.67%)
         occurrences all number
    6
    4
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    5 / 55 (9.09%)
    4 / 60 (6.67%)
         occurrences all number
    7
    4
    Back pain
         subjects affected / exposed
    4 / 55 (7.27%)
    2 / 60 (3.33%)
         occurrences all number
    5
    5
    Pain in extremity
         subjects affected / exposed
    4 / 55 (7.27%)
    5 / 60 (8.33%)
         occurrences all number
    4
    8
    Neck pain
         subjects affected / exposed
    3 / 55 (5.45%)
    3 / 60 (5.00%)
         occurrences all number
    4
    3
    Muscle spasms
         subjects affected / exposed
    2 / 55 (3.64%)
    5 / 60 (8.33%)
         occurrences all number
    2
    5
    Limb discomfort
         subjects affected / exposed
    0 / 55 (0.00%)
    3 / 60 (5.00%)
         occurrences all number
    0
    3
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    4 / 55 (7.27%)
    1 / 60 (1.67%)
         occurrences all number
    4
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Strictly Confidential Information and Data. Property of ESTEVE
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 18 09:24:33 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA